oncogenic mutational networks in acute myeloid leukemia (aml) and myelodysplastic syndromes (mds)
Published 7 years ago • 208 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
1:50
germline predispositions in myelodysplastic syndromes (mds) and acute myeloid leukemia (aml)
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
2:31
what is vexas syndrome and what is its association with mds?
-
1:51
factors driving the transformation of chip to mds
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
7:11
treatment of older mds patients with bmt (bone marrow transplantation)
-
7:54
patient/caregiver stories - living with mds
-
5:36
finding hope: mackenzie's story
-
1:10
addressing leukemic transformation in mds: ongoing challenges and future outlooks
-
1:36
insights into the biology of pediatric mds
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
3:23
the prognostic value of idh1 and idh2 in acute myeloid leukemia (aml)
-
2:55
prognostic drivers in aml and mds
-
2:34
the role of ezh2 mutations in mds
-
3:22
performance of the aipss-mds ml model in predicting os & leukemic transformation in cmml
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
3:10
the role of ngs in mds diagnosis
-
1:43
targeting mds stem cells with omacetaxine and azacitidine
-
1:18
key recurrent mutations in mds
-
1:19
the promise of precision medicine in mds
-
2:07
emerging targeted treatments for mds
-
3:36
the genetic landscape of mds: how this is improving & impacting the development of therapies